Hosted on MSN

Novartis to acquire Excellergy for $2bn upfront

Novartis has signed an agreement to acquire biotech business Excellergy, which specialises in the development of next-generation anti-immunoglobulin e (IgE) therapies for up to $2bn in upfront and ...
Fierce Pharma

Fierce Pharma Asia—Novartis’ $7.8B mRNA deal; Shionogi’s $2B buy; ArriVent’s phase 3 flop

Novartis bought an mRNA-coded autoimmune T-cell engager candidate for up to $7.8 billion, as Shionogi offered $2 billion to ...
Pulse 2.0

Novartis: $2 Billion Acquisition Of PI3Kα Inhibitor To Strengthen Breast Cancer Pipeline

Novartis announced that it has agreed to acquire a next-generation PI3Kα inhibitor program from Synnovation Therapeutics in a deal valued at $2 billion upfront, with up to $1 billion in additional ...
NJBIZ

Novartis to buy Excellergy for $2B to boost allergy drugs

Novartis‘ Excellergy deal valued at up to $2 billion, expected to close in H1 2026 Next-generation anti-IgE drug Exl-111 joins allergy lineup Therapy designed for faster, deeper suppression of IgE ...

A Top Novartis (NVS) Shareholder Says ‘The Party is Over’ for its Dealmaking Team

On 10, 2026, Reuters reported that Artisan Partners, among Novartis AG (NYSE:NVS)’ 20 largest shareholders, publicly called for a shake-up of the Swiss drugmaker’s board to improve oversight of its ...
Pulse 2.0

Novartis: $2 Billion Acquisition Of Excellergy To Expand Allergy Drug Pipeline

Novartis announced that it has entered into an agreement to acquire Excellergy, a private biotechnology company focused on next-generation anti-IgE therapies, in a deal valued at up to $2 billion, ...
streetinsider

Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload, expanding options for cancer patients

Strengthens the Novartis oncology pipeline with two lead ADC assets and a broader payload platform with potential impact across multiple solid tumor settings Basel, July 6, 2026 - Novartis today ...